相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template
Yasushi Yamazoe et al.
DRUG METABOLISM AND PHARMACOKINETICS (2021)
Refined CYP2E1 Template system to decipher the ligand-interactions
Yasushi Yamazoe et al.
DRUG METABOLISM AND PHARMACOKINETICS (2021)
Prediction of regioselectivity and preferred order of CYP1A1-mediated metabolism: Solving the interaction of human and rat CYP1A1 forms with ligands on the template system
Yasushi Yamazoe et al.
DRUG METABOLISM AND PHARMACOKINETICS (2020)
Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study
Yasushi Yamazoe et al.
DRUG METABOLISM AND PHARMACOKINETICS (2020)
Applications of a grid-based CYP3A4 Template system to understand the interacting mechanisms of large-size ligands; part 4 of CYP3A4 Template study
Takahiro Goto et al.
DRUG METABOLISM AND PHARMACOKINETICS (2020)
Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions part 3: Difference in substrate specificity of human and rodent CYP1A2 and the refinement of predicting system
Yasushi Yamazoe et al.
DRUG METABOLISM AND PHARMACOKINETICS (2019)
Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans
Vishal Shah et al.
XENOBIOTICA (2019)
Solving the interactions of steroidal ligands with CYP3A4 using a grid-base template system
Takahiro Goto et al.
DRUG METABOLISM AND PHARMACOKINETICS (2019)
Reconstitution of CYP3A4 active site through assembly of ligand interactions as a grid-template: Solving the modes of the metabolism and inhibition
Yasushi Yamazoe et al.
DRUG METABOLISM AND PHARMACOKINETICS (2019)
Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: Solving substrate interactions of CYP1A2 with non-PAH substrates on the template system
Yasushi Yamazoe et al.
DRUG METABOLISM AND PHARMACOKINETICS (2017)
In vitro characterization of 4′-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s
Boram Lee et al.
XENOBIOTICA (2016)
Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 1. Focusing on polycyclic arenes and the related chemicals
Yasushi Yamazoe et al.
DRUG METABOLISM AND PHARMACOKINETICS (2016)
Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances
Shinya Hosaka et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2015)
Effect of CYP2C9 Genetic Polymorphism in a Chinese Population on the Metabolism of Mestranol in vitro
Ji-Hong Hu et al.
PHARMACOLOGY (2015)
In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP
Mizuki Yamane et al.
XENOBIOTICA (2015)
In Vitro Metabolism of Montelukast by Cytochrome P450S and UDP-Glucuronosyltransferases
Josiane de Oliveira Cardoso et al.
DRUG METABOLISM AND DISPOSITION (2015)
Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies
Zhi-Xin Wang et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2014)
CYP2J2 and CYP2C19 Are the Major Enzymes Responsible for Metabolism of Albendazole and Fenbendazole in Human Liver Microsomes and Recombinant P450 Assay Systems
Zhexue Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes
Kaoru Kobayashi et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5
Marie Stiborova et al.
TOXICOLOGY (2012)
Unimolecular and Bimolecular Binding System for the Prediction of CYP2D6-Mediated Metabolism
Kimihiko Sato et al.
DRUG METABOLISM AND DISPOSITION (2012)
Predicting Oxidation Sites with Order of Occurrence among Multiple Sites for CYP4A-mediated Reactions
Yoshiyuki Yamaura et al.
DRUG METABOLISM AND PHARMACOKINETICS (2011)
Development of Two-dimensional Template System for the Prediction of CYP2B6-mediated Reaction Sites
Noriyuki Koyama et al.
DRUG METABOLISM AND PHARMACOKINETICS (2011)
Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order
Yasushi Yamazoe et al.
DRUG METABOLISM REVIEWS (2011)
Metabolism of Sesamin by Cytochrome P450 in Human Liver Microsomes
Kaori Yasuda et al.
DRUG METABOLISM AND DISPOSITION (2010)
Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide
Olga L. Zharikova et al.
BIOCHEMICAL PHARMACOLOGY (2009)
In Vitro Nimesulide Studies toward Understanding Idiosyncratic Hepatotoxicity: Diiminoquinone Formation and Conjugation
Fengping Li et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and (+/-)-Suprofen: A Comparison of Kinetics and Probe Substrate Selection
J. Matthew Hutzler et al.
DRUG METABOLISM AND DISPOSITION (2009)
Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro
Tominaga Fukazawa et al.
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2008)
Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination
David J. Elliot et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes
Sirimas Sudsakorn et al.
DRUG METABOLISM AND DISPOSITION (2007)
Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9
Charles W. Locuson et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2006)
Characterization of human liver cytochrome P450 enzymes involved in the metabolism of rutaecarpine
SK Lee et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2006)
In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes
TM Cho et al.
DRUG METABOLISM AND DISPOSITION (2006)
CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin
TM Bland et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic α,β-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme
K Kassahun et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2005)
Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein
Ü Yasar et al.
XENOBIOTICA (2005)
Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism
HR Winter et al.
DRUG METABOLISM AND DISPOSITION (2005)
Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes
A Nakashima et al.
XENOBIOTICA (2005)
Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro:: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism
JH Shon et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes
K Nakamura et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
The structure of human cytochrome P4502C9 complexed with flurbiprofen at 2.0-Å resolution
MR Wester et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes
MT Donato et al.
DRUG METABOLISM AND DISPOSITION (2004)
Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man
K Tougou et al.
XENOBIOTICA (2004)
Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes
A Ghosal et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2003)
Generation and evaluation of a CYP2C9 heteroactivation pharmacophore
AC Egnell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Crystal structure of human cytochrome P4502C9 with bound warfarin
PA Williams et al.
NATURE (2003)
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein
DC Evans et al.
DRUG METABOLISM AND DISPOSITION (2003)
In vitro metabolism of chloroquine:: Identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation
D Projean et al.
DRUG METABOLISM AND DISPOSITION (2003)
Metabolism of rofecoxib in vitro using human liver subcellular fractions
D Slaughter et al.
DRUG METABOLISM AND DISPOSITION (2003)
Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation
SL Born et al.
DRUG METABOLISM AND DISPOSITION (2002)
Interaction of new sulfaphenazole derivatives with human liver cytochrome P4502Cs: Structural determinants required for selective recognition by CYP2C9 and for inhibition of human CYP2Cs
NT Ha-Duong et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2001)
Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine
OV Olesen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Inhibition selectivity of grapefruit juice components on human cytochromes P450
W Tassaneeyakul et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Identification of cytochrome P450 isoform involved in the metabolism of YM992, a novel selective serotonin re-uptake inhibitor, in human liver microsomes
K Noguchi et al.
XENOBIOTICA (2000)
CYP2C9 Ile(359) and Leu(359) variants: enzyme kinetic study with seven substrates
K Takanashi et al.
PHARMACOGENETICS (2000)
分享论文
